Biomimetic Nanotechnology for SARS-CoV-2 Treatment
More than 600 million people worldwide have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in the pandemic of coronavirus disease 2019 (COVID-19). In particular, new waves of COVID-19 caused by emerging SARS-CoV-2 variants pose new health risks to the glob...
Main Authors: | Shuo Li, Xue Liu, Gang Liu, Chao Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/15/3/596 |
Similar Items
-
SARS-CoV-2 vaccine research and development: Conventional vaccines and biomimetic nanotechnology strategies
by: Lanxiang Huang, et al.
Published: (2021-03-01) -
Meet changes with constancy: Defence, antagonism, recovery, and immunity roles of extracellular vesicles in confronting SARS‐CoV‐2
by: Xiaohang Chen, et al.
Published: (2022-12-01) -
Think like a Virus: Toward Improving Nanovaccine Development against SARS-CoV-2
by: Nura A. Mohamed, et al.
Published: (2022-07-01) -
Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
by: Sicong Yu, et al.
Published: (2021-06-01) -
SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
by: T.M. Abdelghany, et al.
Published: (2021-03-01)